Short answer
Verastem, Inc. (VSTM) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $19M with net income of −$37M.
Q1 2026 key financials · XBRL
- Revenue
- $19M
- Net income
- −$37M
- +29.8% YoY
- Operating margin
- -240.5%
- EPS (diluted)
- −$0.46
- +52.1% YoY
Source: XBRL data from the Verastem, Inc. (VSTM) Q1 2026 10-Q on SEC EDGAR. USD.
Verastem, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $18.7M, versus $0 YoY, entirely from AVMAPKI FAKZYNJA CO-PACK
- Product gross margin approximately 83.9%, with $18.7M revenue and $2.8M product cost
- Net loss $36.6M versus $52.1M YoY, while operating loss was $44.9M versus $44.2M
- Cash, equivalents and investments $181.7M; operating cash outflow $52.1M versus $38.7M YoY
- Substantial going-concern doubt following initiation of TARGET-D 201, 202 and 203 and higher projected R&D costs
Risk Factors
- New going-concern risk triggered by ASC 205-40 assessment, despite potential 12-month funding sufficiency
- Liquidity risk: operating cash use rose to $52.1 million from $38.7 million year over year
- Financing risk: $75.0 million Note Purchase Agreement borrowings carry floating-rate interest
- Operational risk: insufficient capital could delay or eliminate AVMAPKI FAKZYNJA CO-PACK commercialization and clinical trials
- Market risk: $181.7 million cash, cash equivalents, and investments exposed to interest-rate changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Verastem, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.